Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
about
Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis CInterferon-Free Treatments for Chronic Hepatitis C Genotype 1 InfectionEntry inhibitors: New advances in HCV treatmentExploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replicationNetwork meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24.Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma.Real world efficacy and safety of ombitasvir, Paritaprevir/r+Dasabuvir+Ribavirin IN genotype 1B patients with HCV liver cirrhosis.Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease InhibitorOmbitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.Chemical genetics-based development of small molecules targeting hepatitis C virus.Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider.Ritonavir-Induced Suicidal Death of Human Erythrocytes.
P2860
Q26745769-BC89B54B-F0F3-45EF-A284-1E6F31A52DBEQ26746563-BE867C0D-04B3-4A15-A817-91B35B758005Q26770817-6EE2BF6B-BFB8-4919-88BC-816F364199CFQ28830384-49BB6321-DE91-43CE-A35D-D73593AE8B5AQ36167257-F1234058-F193-4387-BAC7-3F8926DB9079Q36621548-653018CB-9CC0-404D-A510-76A12047F456Q38620762-1B686B8F-991C-45ED-BA48-E8D8EC9BF398Q38714640-D044F79B-D1F8-43E9-8A62-BA91DCA48637Q38893128-D587C513-7812-4ABE-B576-0A97B825640DQ40063790-9CDBF256-98E9-4AF8-ABC6-8CEF78AF0992Q40409263-0504E540-B4A1-4D46-8F22-A24957331BCFQ40548267-B7329D8C-B6F3-4569-A12B-3380AC0F3E57Q40773451-0AC5F256-AC2C-4132-8E46-E4B4672DDF08Q41923104-42C52B8E-51F9-46BB-80D8-855466C6802FQ46537249-32E00D5A-6838-4628-8B86-5B751592447E
P2860
Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Ombitasvir/Paritaprevir/Ritona ...... onic HCV Genotype 1 Infection.
@en
type
label
Ombitasvir/Paritaprevir/Ritona ...... onic HCV Genotype 1 Infection.
@en
prefLabel
Ombitasvir/Paritaprevir/Ritona ...... onic HCV Genotype 1 Infection.
@en
P2860
P1433
P1476
Ombitasvir/Paritaprevir/Ritona ...... onic HCV Genotype 1 Infection.
@en
P2093
Emma D Deeks
P2860
P2888
P304
P356
10.1007/S40265-015-0412-Z
P577
2015-06-01T00:00:00Z
P6179
1043787782